Veradermics to present phase 3 hair loss trial results Monday

New Haven, Conn. - Veradermics, Inc. (NYSE: MANE) is set to hold an investor call on Monday at 8:00 a.m. ET to discuss the results from Part A of its Phase 3 clinical trial assessing the efficacy of VDPHL01 in treating pattern hair loss, according to a press release. The randomized, double-blind, placebo-controlled study, known as Study 304, included more than 500 male participants with mild-to-moderate pattern hair loss.

The trial evaluated an extended-release oral minoxidil formulation, specifically VDPHL01, at two different dosages. VDPHL01 is an investigational drug currently in Phase 3 development for both male and female pattern hair loss. The company's registration-directed clinical development program includes three multicenter trials involving over 1,600 adult males and females with mild-to-moderate pattern hair loss.

Each trial lasts 52 weeks, with a six-month placebo-controlled period followed by an additional six-month extension. The trials aim to support potential FDA approval of VDPHL01, which, if approved, would be the first FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female populations. The investor call will be available on the company's website, with a replay provided afterward.